Dr. Michael Har-Noy Details Remarkable Results in Breast Cancer Treatment

24 Jan

Dr. Michael Har-Noy says that the immune mechanism of an allogeneic stem cell transplant is very effective in destroying chemotherapy-resistant metastatic tumors despite their immunoavoidance mechanisms, but this tumor-killing immune effect is unfortunately closely linked to the very lethal graft versus host disease (GVHD) and is thus of limited clinical use.


Dr. Michael Har-Noy, founder and C.E.O. of Immunovative Therapies Ltd., a biotech company in Israel, has developed a revolutionary new drug, AlloStimTM, that elicits a host anti-tumor response without causing GVHD toxicity.  Dr. Michael Har-Noy describes how this drug was recently tested in an FDA-approved Phase I/II trial of 42 late-stage metastatic cancer patients with a variety of different tumors.   Most study patients showed evidence of improved survival and immune-mediated tumor destruction and experienced only minor side effects. Conventional RECIST criteria tended to overestimate tumor size because responding lesions swelled and appeared larger on computed tomographic scan.


Dr. Michael Har-Noy noted that serum interleukin 12 (IL-12) levels were identified as the best predictor of a positive response to AlloStimTM.   Fifty percent of patients treated with Dr. Michael Har-Noy’s proprietary drug were  IL-12 positive and survived a median of 211 days, compared with 131 days for IL-12 negative patients.   Nine of 16 refractory metastatic breast cancer patients exhibited adequate IL-12 levels. The HER2+ subset of  five breast cancer patients were all IL-12 positive and had a median survival of 416 days, while the 11 HER2- patients had a median survival of only 134 days


Dr. Michael Har-Noy points out that HER2+ breast malignancies usually spread faster and have a worse prognosis than HER2- tumors. The superior response to allogeneic cell treatment in the HER2+  metastatic breast cancer patients may result from the high quantities of anti-HER2 antibodies exhibited by this patient subset.   Theoretically, treatment with AlloStimTM should potentiate the ability of these HER2+ antibodies to cause tumor destruction.


This preliminary study describes a dramatically increased survival time in a gravely ill subset of breast cancer patients with a very short life expectancy.  Dr. Michael Har-Noy  will ultimately conduct a randomized, double-blind Phase II/III study of AlloStimTM this unique treatment in metastatic breast cancer patients.


In Bangkok, Thailand, Dr. Michael Har-Noy is now conducting a combined Compassionate Use-Phase I/II Trial of CRCL-AlloVaxTM, a personalized anti-cancer vaccine.  Interested patients may read about and register for the trial at www.immunocare.net.


Sources: www.immunocare.net, www.michaelhar-noy.com, www.immunovative.co.il


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: